Floatz logo

Pasifolate Exatecan

Endometrial Carcinosarcoma

Elucida OncologyOtherPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Endometrial Carcinosarcoma cohort.

Asset / SponsorPhaseRating
Carboplatin
GOG Foundation
Phase 3B
Ifosfamide
GOG Foundation
Phase 3B
Ziv-Aflibercept
National Cancer Institute (NCI)
Phase 2B
Sorafenib
National Cancer Institute (NCI)
Phase 2B
Dostarlimab
ARCAGY/ GINECO GROUP
Phase 2/3B

View all 14 →

Same molecule, other indications

Pasifolate Exatecan is also rated in:

ovarian disorderDormant
CCC
Indicative ·
48 / 100
View asset →
ovarian adenocarcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
endometrial disorderDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →